Considering that SHP2 plays a critical role in the progression of BRAFV600E mutant thyroid cancer, vemurafenib in combination with small molecule inhibitors targeting SHP2 may be a promising therapeutic strategy for the treatment of BRAFV600E mutant thyroid cancer. Here, PTPN11 is linked to thyroid gland carcinoma.